Pressrelease published on the CymaBay Seladelpar study!

Take the opportunity to read the pressrelease on the CymaBay study with Seladelpar in the NIF mouse.  Ed Cable, sr. Director of Research at CymaBay Therapeutics, gives his view on why CymaBay chose to work with the NIF mouse, and comments on the positive results. You will find the full pressrelease here.

Pressrelease published on the CymaBay Seladelpar study!2021-12-08T12:38:55+01:00

Check out CymaBay Therapeutics poster on the NIF mouse at AASLD!

We are very happy that CymaBay Therapeutics chose to present the convincing data from their study in the NIF mouse. They nicely show that Seladelpar, which is a substance in clinical studies, reduces fibrosis in the NIF mouse in both liver and kidney. You will find the PDF of the poster "Seladelpar reduces established liver [...]

Check out CymaBay Therapeutics poster on the NIF mouse at AASLD!2021-11-15T11:19:32+01:00

The NIF mouse in Cyma Bay preclinical study using Seladelpar

We are happy and proud that our NIF mouse is the model used in the preclinical poster presented by Cymabay Therapeutics at the upcoming AASLD meeting, with the title "Seladelpar reduces established liver and renal fibrosis in the non-obese diabetic inflammation and fibrosis (NIF) mouse model"Take a look at the press release here!

The NIF mouse in Cyma Bay preclinical study using Seladelpar2021-10-18T10:25:07+02:00

InfiCure Bio will participate with a poster at EASL NAFLD Summit on September 16-17

Inficure Bio will attend the EASLE NAFLD Summit, and present a poster on the NIF mouse. Don't miss the opportunity to take part of the latest updates on how to use the NIF mouse  for preclinical testing of new NASH drugs. Take a look at the poster "The NIF mouse – a unique way to [...]

InfiCure Bio will participate with a poster at EASL NAFLD Summit on September 16-172021-09-17T14:55:09+02:00
Go to Top